Background: Recent evidence suggests that succinate, long known as an intermediate in the citric acid cycle, may also have a role as a signaling molecule through GPR91 and that activation of this receptor results in blood pressure (BP) elevation via the renin-angiotensin system. We sought to test the hypothesis that GPR91 contributes to BP elevation in hypertension. In addition we investigated whether elevated succinate in diabetes could contribute to the increased rate of gluconeogenesis in that condition.
A s an intermediate in the citric acid cycle, 1 succinate (SA) occupies a central role in energy metabolism. Recently SA has been shown to be an activating ligand for GPR91, a G-protein coupled receptor most abundantly expressed in the renal cortex. 2 Intravenous administration of SA into mice 2 or humans 3 causes elevation of blood pressure (BP). In mice this effect has been shown to be mediated by GPR91 and to require activation of the renin-angiotensin system. 2 Therefore, GPR91 activation has the potential to elevate BP in hypertensive disease. We set out to test the hypothesis that SA is elevated in hypertension sufficient to activate GPR91.
Insulin increases the oxidation of SA in hepatocytes and cells from diabetic animals are resistant to this effect, 4 suggesting the potential for elevated SA in this disease state. Succinate has been reported to stimulate gluconeogenesis, 5 but it is not known whether GPR91 plays any role in this effect. Because diabetes is a condition characterized in part by enhanced gluconeogenic flux, we tested the hypothesis that elevated SA in diabetes provides a link between reduced citric acid cycle flux and gluconeogenesis.
Animal models of human diseases have proved invaluable in understanding disease processes and in the development of therapeutic agents. However, it is important to understand the extent to which any model reflects or differs from human physiology and the human disease state. Therefore we set out to measure SA in human hypertensives and diabetics, as well as control subjects for comparison to the data obtained in rodent models.
Little information is available detailing the concentration of SA in metabolic disease. However, in one report describing a liquid chromatography with ultraviolet detection method for assay of carboxylic acids in urine, comparison is made between a single normal subject and a single diabetic subject and the data presented indicates elevated SA in the diabetic. 6 However, it is not known whether this isolated observation would also be true in a more statistically meaningful comparative study. We set out to compare SA concentration in rodent models of metabolic disease and in human type 2 diabetics in comparison to nondiabetic controls in a more statistically rigorous way than has been done previously.
Methods

Measurement of Succinate by Liquid Chromatography Tandem Mass Spectrometry
A liquid chromatography method coupled with tandem mass spectrometric detection was developed for quantitation of SA in biofluids using SA containing three deuterium atoms (d3-SA) as an internal reference standard. Chromatographic separation was carried out on a reverse phase analytical column before detection on a triple quadrupole mass spectrometer monitoring the specific mass of SA and d3-SA and their respective product ions. The mass/charge ratios (m/z) for these were SA 117 and 99; d3-SA 120 and 102.
One hundred microliters of the sample was acidified with 100 L of 1 mol/L HCl and after addition of internal standard d3-SA (50 L of 34 nmol/L) was extracted with 800 L of methyl-t-butyl ether. The ether layer was removed and dried under nitrogen, then reconstituted in 100 L of 0.1% formic acid and 5 L injected on an HPLC column (Echelon C18 2 mm ϫ 100 mm; 4-m particle size; Analytical Inc., Pompton Plains, NJ) using a Shimadzu SCL-10 Avp controller system (Addison, IL) coupled to an ABI 4000 triple quadrupole mass spectrometer operating in negative ion mode. The mobile phase consisted of solvent A (0.1% formic acid/10 mmol/L ammonium formate) and solvent B (methanol) at a flow rat of 0.2 mL/min. A linear gradient of 5% to 50% methanol was applied during 2 min, then held at 50% for an additional 1.5 min. At the end of the run, methanol was decreased to 5% for 0.2 min, and held at 5% for 1.3 min for column re-equilibration. The liquid chromatography tandem mass spectrometry (LC-MS/MS) chromatograms were generated for both SA and d3-SA and were integrated to calculate peak areas. The SA peak area was expressed as the area relative to that of the internal d3-SA standard. A calibration curve was constructed by adding known concentrations of SA to pooled blank matrix (plasma or serum). The LC-MS/MS data were processed and concentrations were calculated using the Analyst 1.1 software (Applied Biosystems, Foster City, CA). Under the chromatography conditions used, SA had a retention time (Rt) of approximately 2.75 min (Fig. 1) . The use of mass transitions specific to SA (m/z ϭ 117 to 99) and d3-SA (m/z ϭ 120 to 102) in triple quadrupole mass spectrometry under optimized ionization conditions produced a sensitive and quantitative detection of SA in biological matrix. The use of a d3-SA internal standard (structurally identical but differing in mass) corrected for any sample-to-sample variation in extraction efficiency or instrument sensitivity. Quantitation of SA was linear for the range 0 to 85 mol/L with a detection limit of Յ0.85 mol/L. Sample recovery was 90% to 110% and the precision as measured by the coefficient of variation for triplicate samples was Ͻ10%. Due to the use of mass and fragmentation products unique to SA, there was no significant interference from closely related species such as methylmalonate (3MMA). Although the precursor mass of both SA and 3MMA are the same (m/z ϭ 117), the collisionally activated dissociation of SA generates a product ion of m/z ϭ 99 used in quantitation, which is not generated by 3MMA.
Rodent Models of Hypertension and Metabolic Disease
The study was performed in accordance with guidelines established for animal experimentation by the Pfizer Institutional Animal Care and Use Committee, fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International. Male spontaneously hypertensive rats (SHR) and normotensive controls (Wistar Kyoto, WKY) at 19 weeks of age (Charles River Laboratories, Wilmington, MA), male fa/fa (fatty Zucker) rats and lean controls at 14 weeks of age (Harlan, Indianapolis, IN), male C57BL/ 6J-ob/ob mice and lean controls at 9 weeks of age (Harlan), and male C57BL/KS-db/db mice and lean controls at 10 weeks of age (Harlan) were used for obtaining plasma samples for determining SA levels. All animals were housed under constant temperature (21°C) and humidity (50%) and exposed to a 12 h light-dark cycle at our laboratory animal research facility. Animals were allowed free access to standard chow (Rodent 5001, Purina, St. Louis, MO) and water. Unless specified, animals were not fasted before blood collection. All blood samples were collected in tubes with lithium heparin (Becton Dickinson and Company, Franklin Lakes, NJ), except where otherwise specified. Plasma was prepared by centrifugation at 2360 g for 5 min at 4°C, and stored at Ϫ80°C until analysis. 7 were selected for serum SA assay. All subjects had documented coronary atherosclerotic disease. Blood pressure was measured using an appropriately sized cuff, with the arm supported at the level of the heart, and recorded to the nearest mm Hg. Serum samples taken before the initiation of the test treatment (amlodipine or placebo) were used for measurement of SA. Precise details of the inclusion and exclusion criteria for this trial have been published previously. 8 To compare diabetics and nondiabetics, subjects were recruited with the following physical inclusion criteria: men or women, aged 25 to 55 years, body weight Ͼ110 lbs, body mass index (BMI) 25 to 35. Healthy subjects had no disease as identified by full physical examination and clinical laboratory tests. Type 2 diabetes was as defined by the National Diabetes Group 9 : fasting plasma C-peptide Ն0.4 nmol/L, glycosylated hemoglobin (HbA 1c ) between 7.5% and 10%, fasting serum glucose between 130 and 180 mg/dL, no change in treatment regimen in the past 2 months before the study, treatment with no more than two antidiabetic medications and not on maximal dose for both, and documented absence of proliferative retinopathy or macular edema within 1 year of study. A single baseline BP measurement was made in the subject's writing arm, using an appropriately sized cuff, with the arm supported at the level of the heart, and recorded to the nearest mm Hg. Data are shown as mean Ϯ SEM.
All human subjects gave written informed consent, and the studies were approved by the Institutional Review Committees at all sites.
Results
Succinate Measurement and Sampling Methodology
In preliminary experiments rat plasma SA concentration (125 to 250 mol/L) was approximately 40-fold higher than that measured in human serum samples. These rat samples were collected under CO 2 euthanasia, whereas the human samples were collected from conscious subjects. Hence we investigated the influence of collection conditions on measured SA concentration in the SHR. We tested the effect of nutritional status, anesthetic, and sampling site on measured SA concentration. These data showed that sampling site influences measured SA value and that anesthesia using 100% CO 2 causes an elevation of SA (Table 1) . In a separate experiment in catheterized, conscious rats (Sprague-Dawley and SHR strains), SA levels were also found to be higher in venous versus arterial blood (data not shown). The SA in retro-orbital sinus blood (a mixture of arterial and venous) from SHR anesthetized with isoflurane under well-oxygenated conditions is lower in comparison to that obtained from the tail vein of conscious SHR (compare data in Table 1 and Fig. 2A ). Nutritional status did not appear to influence circulating SA. For these reasons care was taken to obtain all subsequent samples for SA measurement under well-oxygenated conditions and to ensure that comparison of disease models and their controls was only made between samples taken identically from age-matched or littermate controls handled in exactly the same way. A study to investigate the effect of anticoagulant and sample stability on measured SA showed that plasma anticoagulated with either heparin or EDTA give equivalent results to serum and that SA in these samples is stable at least up to 22 h at room temp. Succinate concentration in rat plasma was stable during at least two freeze-thaw cycles. Whole blood contains a similar SA concentration to plasma indicating that SA is in equilibrium across the erythrocyte membrane.
Succinate in Rodent Models of Hypertension and Metabolic Disease
Measured SA concentration in the plasma from various rodent models of hypertension and metabolic disease is shown in Fig. 2 . In each case, a statistically significant elevation of SA concentration was found in the disease model compared to its control. Most markedly SHR have a 3.6-fold increase in plasma SA compared to that measured in WKY rats.
Succinate in Human Hypertensives
Baseline data for these subjects is shown in Table 2 . Human hypertensives had serum SA levels that were not significantly different from a well-matched control group of subjects (Fig. 2E) . Despite use of antihypertensive medications in the majority of the hypertensive subjects selected (Table 2) , their systolic BP was on average Ͼ45 mm Hg higher than the control subjects, and diastolic BP was Ͼ20 mm Hg higher than controls. On an individual subject basis there was no significant correlation between serum SA and systolic or diastolic BP (Fig. 3A,B) , nor with BMI (Fig. 3C ) within either group and no correlation with number of antihypertensive medications within the hypertensive group (Fig. 3D) . To investigate the possibility that the significantly higher triglyceride levels in the hypertensive group was obscuring a difference in SA between the groups for an unknown reason we examined the data for a negative correlation between triglyceride and SA and none was found (data not shown).
Succinate in Human Diabetics
Baseline data for these subjects is shown in Table 3 . Diabetics did not have elevated serum SA in comparison to nondiabetic subjects, and SA was essentially identical in the fasted condition and 60 min after a meal (Fig. 2F) . These data are consistent with our findings in rat that nutritional status does not affect circulating SA. There was no correlation between fasting or postprandial SA and BP on an individual subject basis within either control or diabetic groups (Fig. 4 ).
Discussion
This study shows for the first time that hypertension or metabolic disease in rodents is accompanied by substantial increases in circulating SA. The concentration of SA in the venous circulation of healthy rodents as measured in this study was in the range of 6 to 17 mol/L. The reported EC 50 of GPR91 for SA in cell-based assays is in the range of 28 to 69 mol/L 2 indicating that the circulating SA concentration is in exactly the range where an increase could result in activation of GPR91. Further testing of the role of SA activation of GPR91 will require demonstration that antagonism, downregulation, or deletion of GPR91 decreases BP in hypertensive models or ameliorates the metabolic profile in insulin-resistant or diabetic rodents. The lack of demonstration of elevated SA in human hypertension or diabetes does not exclude the possibility of GPR91 activation as the result of a localized increase in SA in the immediate vicinity of the receptor, but which is not reflected in the peripheral circulation. However, measurement of the localized concentration of SA was beyond the scope of the current study. One caveat attached to the data obtained from PREVENT trial subjects is that all individuals studied had documented coronary artery disease and this may have obscured any difference in SA concentration related to hypertension per se. However, based on the data available, with respect to elevation of circulating SA, rodent models do not appear representative of human hypertension or human diabetes.
Because SA was elevated in the rodent model of hypertension and in the metabolic models, it is important to consider whether the finding in the metabolic models could reflect underlying hypertension rather than the metabolic aspects of the models. The db/db mice are reportedly hypertensive, as measured by tail-cuff plethysmography in some reports, 10 but not others. 11 In rats obesity is associated with elevated BP measured by the tail-cuff method, but not by telemetry, 12 suggesting that, at least in some circumstances, obesity can cause an exaggerated hemodynamic response to stress rather than hypertension per se. 12 In addition, ob/ob mice are reported to be slightly hypotensive with respect to their lean control littermates as measured by telemetry. 13 The fa/fa rat is obese and insulin resistant, although not overtly diabetic. Taken together with our findings these observations strongly suggest an association of diabetes or obesity per se with elevated SA levels independent of hypertension in rodents.
In addition to being an intermediate in the citric acid cycle, SA can also be generated from ␣-ketoglutarate through nonenzymatic decarboxylation by reactive oxygen species, 14 and therefore increased levels may reflect underlying oxidative stress in these models, as reported previously. 15 Further work would be required to test this hypothesis. Succinate is both a product and a feedback inhibitor of the enzyme prolyhydroxylase (PHD), which modulates the hydroxylation state of hypoxia-inducible factor (HIF1␣) and expression of genes involved in the cellular response to hypoxia. 16 Because hypertension has been associated with hypoxia in some tissues, 17 elevated SA levels could be the result of increased oxidative stress and act to induce antihypoxia protective mechanisms. It would therefore be of substantial interest to know whether HIF1␣-inducible genes are activated in any or all of the rodent models studied in this article.
In general, SA concentrations were lower in human subjects than in rodents. This was also true of freshly drawn human samples, indicating that the apparent species difference in SA concentration is not the result of degradation during storage of serum samples. In contrast to rodent models, neither human hypertension nor diabetes was associated with an increase in circulating SA. It should be noted that there was no difference in the BMI of the diabetic patients in comparison to controls and therefore the possibility remains that SA may be elevated in obese humans compared to lean controls.
